Bergen, 10 August 2006: NorDiag ASA has entered into a collaboration with Genpoint AS to further enhance its position as a leader in gene based colon cancer diagnostics. Genpoint will assist NorDiag in automating and improving NorDiag`s method for isolation of human DNA from stool. NorDiag`s goal is to supply an integrated solution containing instruments, software and reagents to its future laboratory partners.

-Extracting human DNA from stool is a challenging task, as human DNA accounts for less than one percent of total DNA in the samples. There are few established industry practices in this area, and although we are already leading the field we believe this collaboration will further enhance our competitive position, says CEO Christian Horn in NorDiag.

-It is important for us to deliver an integrated and automated solution to our laboratory partners, in order to secure reproducibility of test results. Sale of reagents and instruments will accelerate revenues for our Company, says Horn.

Earlier this year, NorDiag entered into collaboration with US biotech company Transgenomic Inc (Nasdaq:TBIO), and now employs their leading WAVE system for detection of mutations in NorDiag`s panel of proprietary and in-licensed markers for colorectal cancer.

-We have secured excellent partners in each area with Transgenomic and now Genpoint, and continuous improvements within DNA isolation and mutation detection will be crucial to retain our technological advantage and further strengthen our competitive position, says Horn.

-Preparation of samples for cancer diagnostics is a prioritized field for Genpoint. NorDiag is a leading player in its niche and we are pleased to be their partner of choice, says CEO Erik Hornes in Genpoint. F

For further information, please contact:
CEO Christian Horn, NorDiag ASA, +47 90 16 31 53

About NorDiag:
NorDiag is a biotechnology company with a focus on the early detection of cancer. The company`s first product is GenefecTM, a genetic test for early detection of gastro intestinal cancer, including colorectal cancer. NorDiag is listed at the Oslo Stock Exchange with the ticker NORD. For more information, please www.nordiag.no

About Genpoint AS:
Genpoint specializes in automated sample preparation of DNA from difficult biological samples such as stool. The company`s patented `Bugs`n Beads` technology is based on specially coated paramagnetic particles capable of isolating virtually any organism from almost any matrix. For more information, please see www.genpoint.com